Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 4:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	11/26/2007 10:08:08 AM
	of 285

Cardiome Pharma updates guidance (CRME) 10.48 : Co announces updated guidance for expected interim results from its Phase 2b clinical trial for vernakalant (oral). Cardiome had originally intended to complete and disclose the interim analysis in Q407. Co has decided to complete and disclose the interim analysis in March 2008, with the final study results to be presented in mid-2008. "While we remain blinded to the efficacy data from the ongoing study, we do know that a significant proportion of our enrollment has occurred in the past two months, meaning that those patients have not yet progressed deeply into the 90-day program," stated Doug Janzen, President and Chief Business Officer of Cardiome. "By delaying one quarter we expect to add roughly 20% more patients into the interim analysis than originally planned, and as a result more data will be available on patients with longer-term exposure. More than 400 patients have been randomized in the study, and enrollment is expected to be complete in early 2008." finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next